Search

Your search keyword '"Douglas B. Flieder"' showing total 2 results
Start Over Author "Douglas B. Flieder" Publisher bmc
2 results on '"Douglas B. Flieder"'

1. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

Author

David L. Rimm, Gang Han, Janis M. Taube, Eunhee S. Yi, Julia A. Bridge, Douglas B. Flieder, Robert Homer, Anja C. Roden, Fred R. Hirsch, Ignacio I. Wistuba, and Lajos Pusztai

Subjects
Non-small cell lung cancer, PD-L1, Immunohistochemistry, Triple-negative breast cancer, Atezolizumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.

Published
2019
Full Text
View/download PDF

2. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

Author

Anja C. Roden, Janis M. Taube, Ignacio I. Wistuba, Eunhee S. Yi, Fred R. Hirsch, David L. Rimm, Douglas B. Flieder, Gang Han, Julia A. Bridge, Lajos Pusztai, and Robert J. Homer

Subjects
Oncology, PD-L1, medicine.medical_specialty, animal diseases, Triple Negative Breast Neoplasms, Context (language use), chemical and pharmacologic phenomena, lcsh:RC254-282, B7-H1 Antigen, 03 medical and health sciences, Viewpoint, 0302 clinical medicine, Immune system, Breast cancer, Non-small cell lung cancer, Triple-negative breast cancer, Atezolizumab, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, medicine, Humans, Lung cancer, 030304 developmental biology, 0303 health sciences, biology, business.industry, biochemical phenomena, metabolism, and nutrition, Prognosis, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunohistochemistry, 3. Good health, 030220 oncology & carcinogenesis, biology.protein, bacteria, Female, business, Companion diagnostic
Abstract

The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results